【SUNZEN 0148 交流专区】宏诚生科

tk123

这股有没有人买?昨天成交量一下高像要动，今天就平平，这两天买量多卖量。五月最高达0.39，今天0.28。

[ 本帖最后由 tk123 于 5-6-2009 09:59 PM 编辑 ]

monday32

我留意这只股一些日子了 , 但就是不敢出手买进

刀圣

千万别碰。 在0.31我就注意到它做票了，全部都是自己吃自己的票，本来0。33想玩contra的， 爸说这种股没有实质的东西，不懂公司地怎样，第二天它就炒上来出票了，0。39放着下，应该很多人中招。倒不如炒一些热门的，自己了解的公司。

icy97

SUMMARY OF KEY FINANCIAL INFORMATION

31/03/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/03/2012	31/03/2011	31/03/2012	31/03/2011
		$$'000	$$'000	$$'000	$$'000
1	Revenue	8,153	7,555	8,153	7,555
2	Profit/(loss) before tax	590	792	590	792
3	Profit/(loss) for the period	419	624	419	624
4	Profit/(loss) attributable to ordinary equity holders of the parent	419	624	419	624
5	Basic earnings/(loss) per share (Subunit)	0.28	0.42	0.28	0.42
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2000		0.2000

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2012	30/06/2011	30/06/2012	30/06/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	7,947	7,891	16,100	15,446
2	Profit/(loss) before tax	363	563	953	1,355
3	Profit/(loss) for the period	240	415	659	1,039
4	Profit/(loss) attributable to ordinary equity holders of the parent	240	415	659	1,039
5	Basic earnings/(loss) per share (Subunit)	0.16	0.28	0.44	0.70
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2000		0.2000

icy97

SUNZEN BIOTECH BERHAD

EX-date	05/12/2012
Entitlement date	07/12/2012
Entitlement time	05:00:00 PM
Entitlement subject	Interim Dividend
Entitlement description	An interim tax-exempt dividend of RM0.006 per ordinary share of RM0.10 each in respect of the financial year ending 31 December 2012
Period of interest payment	to
Financial Year End	31/12/2012
Share transfer book & register of members will be	to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no	Symphony Share Registrars Sdn Bhd Level 6 Symphony House Block D13, Pusat Dagangan Dana 1 Jalan PJU 1A/46 47301 Petaling Jaya Selangor Darul Ehsan Tel: 603.7841.8000
Payment date	24/12/2012
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	07/12/2012
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.006

icy97

SUNZEN BIOTECH BERHAD

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	SUNZEN BIOTECH BERHAD (“Sunzen”) or (“the Company”) - STATUS UPDATE ON THE MEMORANDUM OF UNDERSTANDING (“MOU”) BETWEEN SUNZEN FEEDTECH SDN BHD (“SFSB”) AND UNIVERSITI SAINS MALAYSIA (“USM”)
Reference is made to the Company’s financial results made on 30 August 2012 in relation to the MOU entered between SFSB and USM for the research collaboration on development and pre-commercialisation of a new organic acid blend for enhancement of growth performance and disease resistance in farmed aquatic animals without the use of antibiotics. The Board of Directors of Sunzen wishes to inform that RM850,000 out of the total Technofund grant of RM1.155 million approved by the Ministry of Agriculture (“MOA”) for the above project is allocated for installation of a pilot plant and the remaining balance for market testing and evaluation and also for related operating cost. Installation of a pilot plant has been completed in milestone 1. The project is now in milestone 3 involving product testing under commercial shrimp marine production. A farm has confirmed to allow Orgacids-AQUA to be tested by USM research team.

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	SUNZEN BIOTECH BERHAD (“Sunzen”) or (“the Company”) - STATUS UPDATE ON THE MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN UNIVERSITI PUTRA MALAYSIA ("UPM") AND SUNZEN
Reference is made to the Company’s financial results made on 30 August 2012 in relation to the MOU entered between the Company and UPM for the collaboration on research and development work on animal health products. The Board of Directors of Sunzen wishes to inform that UPM managed to obtain some grant for research into production of amino acid for animal use. The Company expects to collaborate with UPM on the project.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2012	30/09/2011	30/09/2012	30/09/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	8,174	7,701	24,274	23,147
2	Profit/(loss) before tax	684	555	1,637	1,910
3	Profit/(loss) for the period	511	431	1,170	1,470
4	Profit/(loss) attributable to ordinary equity holders of the parent	511	431	1,170	1,470
5	Basic earnings/(loss) per share (Subunit)	0.34	0.29	0.78	0.98
6	Proposed/Declared dividend per share (Subunit)	0.60	0.00	0.60	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2012	31/12/2011	31/12/2012	31/12/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	8,522	8,470	32,796	31,611
2	Profit/(loss) before tax	207	472	1,844	2,379
3	Profit/(loss) for the period	238	290	1,408	1,757
4	Profit/(loss) attributable to ordinary equity holders of the parent	238	290	1,408	1,757
5	Basic earnings/(loss) per share (Subunit)	0.16	0.19	0.94	1.18
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.60	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2000		0.2000

icy97

SUNZEN BIOTECH BERHAD

Type	Announcement
Subject	OTHERS
Description	SUNZEN BIOTECH BERHAD (“SUNZEN” or “the Company”) - Letter of Demand for Breach of Distribution Agreement
The Board of Directors of SUNZEN wishes to announce that on 26 February 2013, Sunzen Lifesciences Sdn. Bhd. (“SLSB”), a wholly-owned subsidiary of the Company was served with a Letter of Demand for breach of Distribution Agreement dated 18 January 2010 (“DA”) entered between Regaplus (Beijing) Investment Consultant Co. Ltd. (“RICCL”) and SLSB pertaining to the appointment of RICCL as one of the distributors to promote and market animal feed supplement products (“Orgacids”) in the People’s Republic of China. Based on the Letter of Demand, RICCL claimed that: a.      the new terms and conditions pertaining to the sale of the Orgacids (“New Terms and Conditions”) imposed by SLSB are contrary to the terms and conditions of the DA; and b.      SLSB had unilaterally and wrongfully terminated the DA when RICCL do not agree to the New Terms and Conditions. RICCL demanded that SLSB shall honour its legal obligations and adhere to the terms and conditions under the DA, failing which, RICCL shall take the necessary steps to protect their interest, including but not limited to commencing legal proceedings and specific performance, and seek the appropriate remedy against SLSB. The Company is seeking solicitor's advice on the necessary course of action to be taken in relation to the aforementioned claims. The Company is not able to ascertain the financial or operation impact for the time being because the amount of claim is not stated in the Letter of Demand and in any event, the Board of Directors is of the opinion that it would not have any material impact to the Group. This announcement is dated 28 February 2013.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/03/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/03/2013	31/03/2012	31/03/2013	31/03/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	8,174	8,153	8,174	8,153
2	Profit/(loss) before tax	797	590	797	590
3	Profit/(loss) for the period	668	419	668	419
4	Profit/(loss) attributable to ordinary equity holders of the parent	668	419	668	419
5	Basic earnings/(loss) per share (Subunit)	0.45	0.28	0.45	0.28
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2013	30/06/2012	30/06/2013	30/06/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	8,553	7,947	16,727	16,100
2	Profit/(loss) before tax	770	363	1,567	953
3	Profit/(loss) for the period	645	240	1,313	659
4	Profit/(loss) attributable to ordinary equity holders of the parent	645	240	1,313	659
5	Basic earnings/(loss) per share (Subunit)	0.43	0.16	0.88	0.44
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

SUNZEN BIOTECH BERHAD

EX-date	23/09/2013
Entitlement date	25/09/2013
Entitlement time	05:00:00 PM
Entitlement subject	Interim Dividend
Entitlement description	Interim Dividend of RM0.008 per ordinary share of RM0.10 each less income tax of 25% in respect of the financial year ending 31 December 2013
Period of interest payment	to
Financial Year End	31/12/2013
Share transfer book & register of members will be	to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no	Symphony Share Registrars Sdn Bhd Level 6 Symphony House Block D13, Pusat Dagangan Dana 1 Jalan PJU 1A/46 47301 Petaling Jaya Selangor Darul Ehsan Tel: 603.7841.8000
Payment date	08/10/2013
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	25/09/2013
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.008

icy97

SUNZEN BIOTECH BERHAD

Type	Announcement
Subject	OTHERS
Description	SUNZEN BIOTECH BERHAD (“Sunzen”) or (“the Company”) - EXTENSION OF TIME FOR THE UTILISATION OF PROCEEDS RAISED FROM THE INITIAL PUBLIC OFFERING (“IPO”)
Reference is made to the Company’s announcement made on 3 October 2012 in relation to the extension of time for the utilisation of proceeds raised from the IPO. As at 31 August 2013, the details of the utilisation of the gross proceeds of RM8 million raised from the IPO are as follows:- Purpose Proposed utilisation RM’000 Actual utilisation RM’000 Balance as at 31 August 2013 RM’000 Intended timeframe for utilisation from the listing date of the Company on 8 October 2008 (Months) Research and development 4,770 4,347 423 36 Overseas expansion 1,000 1,000 - 48 Working capital 430 250 180 24 Estimated listing expenses 1,800 1,980 (180)* 3 Total 8,000 7,577 423 Note: *The actual listing expenses was higher than estimated, the excess amount had been recovered from the partial portion of working capital. The Board of Directors of Sunzen wishes to inform that in view of the existing progress of Research & Development activities of the Group, the utilisation of the balance proceeds of RM423,000 would only be fully utilised by 8 October 2014, and had on 17 September 2013 approved a further extension of time of twelve (12) months up to 8 October 2014 for the utilisation of the aforesaid balance proceeds. This announcement is dated 17 September 2013.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2013	30/09/2012	30/09/2013	30/09/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	8,980	8,174	25,707	24,274
2	Profit/(loss) before tax	1,227	684	2,794	1,637
3	Profit/(loss) for the period	1,042	511	2,355	1,170
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,042	511	2,355	1,170
5	Basic earnings/(loss) per share (Subunit)	0.70	0.34	1.58	0.78
6	Proposed/Declared dividend per share (Subunit)	0.80	0.60	0.80	0.60
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

宏诚生科3股送1凭单

财经新闻 财经  2014-02-18 12:17
（吉隆坡17日讯）宏诚生科（SUNZEN，0148，创业板）建议，每持3股的股东可获赠1免费凭单；最多送出4979万6833张。

截至2月14日，宏诚生科缴足股本为每股面值10仙的1亿4939万500股，同时拥有7万库存股。

宏诚生科指出，派发上述免费凭单是为了回馈投资者，同时也有机会在股东行使凭单时，筹集营运资金。

“假设股东行使全数凭单，公司则会筹得498万令吉，该笔资金将用作于营运资本。”【南洋网财经】

SUNZEN BIOTECH BERHAD

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) BONUS ISSUES
Description	SUNZEN BIOTECH BERHAD (“SUNZEN” OR THE “COMPANY”) PROPOSED FREE WARRANTS ISSUE OF UP TO 49,796,833 FREE WARRANTS IN SUNZEN (“WARRANTS”) ON THE BASIS OF ONE (1) WARRANT FOR EVERY THREE (3) EXISTING ORDINARY SHARES OF RM0.10 EACH IN SUNZEN (“SUNZEN SHARES” OR “SHARES”) HELD AT AN ENTITLEMENT DATE TO BE DETERMINED LATER (“PROPOSED FREE WARRANTS ISSUE”)
On behalf of the Board of Directors of Sunzen (“Board”), TA Securities Holdings Berhad (“TA Securities”) wishes to announce that the Company proposes to undertake the Proposed Free Warrants Issue. Please refer to the attachment below for further details of the announcement. This announcement is dated 17 February 2014. http://www.bursamalaysia.com/market/listed-companies/company-announcements/1540757

Attachments Sunzen- Announcement of Proposed Free Warrants Issue (17.02.2014) -clean.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2013	31/12/2012	31/12/2013	31/12/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	11,619	8,522	37,326	32,796
2	Profit/(loss) before tax	1,381	207	4,175	1,847
3	Profit/(loss) for the period	1,239	238	3,594	1,417
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,239	238	3,594	1,417
5	Basic earnings/(loss) per share (Subunit)	0.83	0.16	2.41	0.95
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.80	0.60
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2200		0.2000

icy97

SUNZEN BIOTECH BERHAD

EX-date	09/04/2014
Entitlement date	11/04/2014
Entitlement time	05:00:00 PM
Entitlement subject	Others
Entitlement description	Issue of up to 49,796,833 free warrants (“Free Warrants”) on the basis of one (1) Free Warrant for every three (3) existing ordinary shares of RM0.10 each in Sunzen held at 5:00 p.m. on 11 April 2014 (“Free Warrants Issue”)
Period of interest payment	to
Financial Year End
Share transfer book & register of members will be	to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no	Symphony Share Registrars Sdn Bhd Level 6, Symphony House Block D13, Pusat Dagang Dana 1 Jalan PJU 1A/46 47301 Petaling Jaya Selangor Darul Ehsan Tel : 03-7841 8000 Fax : 03-7841 8151/52
Payment date
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	11/04/2014
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Ratio
Ratio	1 : 3
Rights Issues/Offer Price

Remarks :

Unless otherwise defined, all terms used shall have the same meaning as those defined in the announcement dated 17 February 2014 in relation to the Free Warrants Issue. The Free Warrants will be credited into the entitled shareholders’ central depository system accounts and notices of allotment will be issued and despatched to the entitled shareholders at the address as per the Record of Depositors within four (4) market days from the entitlement date. Entitled shareholders are not required to take any action. The Free Warrants will be quoted on the ACE Market of Bursa Securities within two (2) market days after an application for the quotation the of Free Warrants is submitted to Bursa Securities. This announcement is dated 28 March 2014

icy97

SUNZEN BIOTECH BERHAD

LISTING'S CIRCULAR NO. L/Q : 70314 OF 2014

Kindly be advised that SUNZEN's 49,756,260 Warrants issued pursuant to the Free Warrants Issue will be admitted to the Official List of Bursa Securities and the listing and quotation of these Warrants on the ACE Market will be granted with effect from 9.00 a.m., Monday, 21 April 2014.

The Stock Short Name, ISIN Code and Stock Number of the Warrants are "SUNZEN-WA", "MYQ0148WAT46" and "0148WA" respectively

Instrument Type	Warrants
Description	Issue of 49,756,260 free warrants (“Free Warrants”) on the basis of one (1) Free Warrant for every three (3) existing ordinary shares of RM0.10 each in Sunzen held at 5:00 p.m. on 11 April 2014 (“Free Warrants Issue”)

Listing Date	21/04/2014
Issue Date	15/04/2014
Issue/ Ask Price	Not Applicable
Issue Size Indicator	Unit
Issue Size in Unit	49,756,260

Maturity Date	14/04/2019
Revised Maturity Date
Exercise/ Conversion Period	5.00Year(s)
Revised Exercise/ Conversion Period
Exercise/Strike/Conversion Price	MYR 0.1000
Revised Exercise/Strike/Conversion Price
Exercise/ Conversion Ratio	1 Warrant: 1 Ordinary Shares of RM0.10 each
Revised Exercise/ Conversion Ratio
Mode of satisfaction of Exercise/ Conversion price	Cash
Settlement Type/ Convertible into	Physical (Shares)

icy97

Type	Announcement
Subject	OTHERS
Description	SUNZEN BIOTECH BERHAD (“SUNZEN” OR “COMPANY”) WAIVER ON THE BUMIPUTERA EQUITY CONDITION
Pursuant to the approval letter from the Securities Commission Malaysia (“SC”) dated 31 March 2008 for the listing of Sunzen on the MESDAQ Market (now known as ACE Market) of Bursa Malaysia Securities Berhad (“Bursa Securities”), Sunzen is required to increase its Bumiputera equity interest in the Company to 30% within five (5) years after being listed or one (1) year after Sunzen has achieved the profit track record requirement for companies applying for listing on the Second Board of Bursa Securities, whichever is earlier (“Bumiputera Equity Condition”). Subsequently, a revision has been made to the Bumiputera Equity Condition including any listing of an MSC-status/BioNexus-status corporation or a corporation with a subsidiary carry MSC-status/BioNexus-status which is a major contributor (more than 50%) to the group’s profitability, business or operations for the most recent financial year are exempted from the Bumiputera Equity Condition. On behalf of the Board of Directors of Sunzen, TA Securities wishes to announce that the SC has waived the Bumiputera Equity Condition vide its letter dated 18 April 2014 on the basis that Sunzen LifeSciences Sdn. Bhd., a wholly-owned subsidiary of Sunzen, is carrying the BioNexus-status and has contributed more than 50% of the group’s profitability. This announcement is dated 21 April 2014.